Devyser Diagnostics

Devyser Diagnostics Interest Coverage

The Interest Coverage Ratio of Devyser Diagnostics (DVYSR.ST) as of Oct 20, 2026 is -10.60. In the previous year, Interest Coverage Ratio was -25.68 — a change of -58.73% (higher).

Interest Coverage

-10.60

YoY

-58.73%

Last updated:

Interest Coverage Ratio of Devyser Diagnostics is 2024 -10.60 . Interest Coverage Ratio of Devyser Diagnostics was 2023 -25.68 . It decreases by -58.73% higher compared to the previous year.

The Devyser Diagnostics Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2018
-5.54 SEK
Jan 1, 2019
13.18 SEK
Jan 1, 2020
-2.87 SEK
Jan 1, 2021
-47.71 SEK
Jan 1, 2022
-190.13 SEK
Jan 1, 2023
-25.68 SEK
Jan 1, 2024
-10.60 SEK
The Devyser Diagnostics Interest Coverage history
YEARInterest CoverageYoY
-10.60-58.73%
-25.68-86.49%
-190.13+298.55%
-47.71+1,563.12%
-2.87-121.76%
13.18-338.12%
-5.54—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Devyser Diagnostics Stock analysis

What does Devyser Diagnostics do? Devyser Diagnostics AB develops and sells genetic testing kits for routine diagnostics, targeting hereditary diseases, oncology, and post-transplantation monitoring. The company offers products like Devyser Thrombophilia assay and Devyser Resolution XY, which analyze DNA for diagnosing genetic conditions and guiding cancer treatment. These kits are sold directly to end customers or through hired distributors across more than 45 countries, with nearly 30 products developed since inception. The firm generates revenue through direct sales and distributor partnerships, focusing on healthcare providers and laboratories that require genetic testing solutions. Its products are used in complex DNA analysis for diagnosing hereditary disorders and optimizing cancer therapies, serving a global market in over 45 countries without relying on third-party brands or external partnerships beyond its own product portfolio. Devyser Diagnostics AB's business model centers on selling its proprietary genetic testing kits, with no mention of additional services or third-party collaborations. The company's revenue streams are derived solely from product sales, targeting healthcare institutions that utilize DNA testing for diagnostic and therapeutic purposes in specialized medical fields. Devyser Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Devyser Diagnostics stock

Interest Coverage Ratio of Devyser Diagnostics is -10.60 in 2024.

Interest Coverage Ratio of Devyser Diagnostics changed from -25.68 to -10.60, representing a -58.73% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Devyser Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Devyser Diagnostics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Devyser Diagnostics

All Key Metrics — Devyser Diagnostics